Abstract
BackgroundAnti-PD-1 immunotherapies (IOs) have robust clinical benefit in a subset of head and neck squamous cell carcinoma (HNSCC) patients and is considered as a standard of care option in the...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
